One of the key components of investing in a Software-as-a-Service company like RingCentral is understanding the dynamic of SaaS vs standalone software. The very fact that revenues are typically recognized on a monthly recurring basis and locked-in to an annual plan makes investing in such a company an attractive proposition. On the other hand, the
A trader walks past a campaign sign for U.S. President-elect Donald Trump and U.S. Vice President-elect Mike Pence on the floor of the New York Stock Exchange (NYSE) in New York, U.S., on Wednesday, Nov. 9, 2016. Michael Nagle | Bloomberg | Getty Images About a third of the S&P 500 companies report earnings, including
“What causes the out-performance of the prosaic old-style stocks over the more exciting trailblazers?” Wharton Business School professor Jeremy Siegel sought to answer that question some 15 years ago in his analysis of dividend stocks. “The answer is simple,” Siegel wrote in The Future for Investors: Why the Tried and True Triumph Over the Bold and
Traders just won’t give up on Luckin Coffee (OTCMKTS:LKNCY). The one-time apparent Starbucks (NASDAQ:SBUX) of China, Luckin stock lost more than 90% of its value this year following revelations of fraud. Source: abolukbas / Shutterstock.com Luckin vastly inflated its reported sales. On the basis of these inaccurate numbers, Luckin sold stock to the public at artificially
For years, Under Armour (NYSE:UAA) has been an eyesore in the otherwise burgeoning athletic apparel market, and Under Armour stock has paid the price. Over the past five years — while Nike (NYSE:NKE) stock has risen 100%, Adidas (OTCMKTS:ADDYY) stock has risen 300% and Lululemon (NASDAQ:LULU) stock has risen 600% — Under Amour has lost
The coefficient of variation (COV) is the ratio of the standard deviation of a data set to the expected mean. Investors use it to determine whether the expected return of the investment is worth the degree of volatility, or the downside risk, that it may experience over time. Dividing the volatility, or risk, of the
After months of clinical trials, Gilead (NASDAQ:GILD) has finally gotten the all clear. As of Thursday afternoon, its remdesivir treatment for the novel coronavirus received full approval from the U.S. Food and Drug Administration. Gilead stock is shooting higher as a result. Source: Casimiro PT / Shutterstock.com This is truly massive news. The antiviral drug
Shares of Vertex (VRTX) declined 20% last week after the company announced the discontinuation of VX-814, the company’s candidate for alpha-1 antitrypsin deficiency. The decline seems disproportionate to the perceived value of this program, but it underscores Vertex’s main weakness – its relatively early-stage and unproven pipeline outside of cystic fibrosis (CF). The stock looks
Billionaire hedge fund manager Paul Tudor Jones has turned more bullish on bitcoin, calling it the best inflation hedge. “I like bitcoin even more now than then. It’s in the first inning and has a long way to go,” Jones said on CNBC’s “Squawk Box” on Thursday. He first revealed his bitcoin investment in May and
A visitor at Intel’s Artificial Intelligence (AI) Day walks past a signboard during the event in Bangalore, India Manjunath Kiran | Getty Check out the companies making headlines after hours Thursday: Intel — Intel shares dropped 10% after the bell on the back of mixed results for the company’s fiscal third quarter. The chip maker
Today we’re going to take a look at investing in IPOs or initial profit offerings. Investing in IPOs is something that people are often attracted to because they think that company could be the next Google, it could be the next Facebook or the next Microsoft, and as those companies increase their value in the
Proctor & Gamble (NYSE:PG) clobbered earnings estimates for its September quarter, but PG stock barely budged. Source: Jonathan Weiss / Shutterstock.com Shares rose just 0.4% during Oct. 20 trading, then lost it overnight. This, after the packaged goods company reported net income of $4.3 billion, $1.63 per share fully diluted, on sales of $19.3 billion.
In my last piece discussing Inovio (NASDAQ:INO) stock, I mentioned reasons to remain positive on the biotech company despite a sharp pullback recently. But it looks like Inovio’s chances for mounting a comeback are slowly slipping away. Source: Ascannio / Shutterstock.com The markets have spoken. They want something concrete from the biotech company before they can
Like many small biotech companies, Aptorum Group (NASDAQ:APM) is definitely a high-risk, high-reward name. But I think the risk-reward ratio for APM stock is favorable at its current levels. Source: Pavel Kapysh / Shutterstock.com On Sept. 29, Aptorum announced that it had made a deal to create novel rapid pathogen identification and detection diagnostics (RPIDD)
Like any type of loan, life insurance policy loans come with pros and cons. It is important to look at both aspects before deciding whether to borrow against your whole life insurance policy. Pros of a Life Insurance Policy Loan Getting a life insurance policy loan is quick and easy. Since you are borrowing against your own assets, there
Snowflake (NYSE:SNOW) made some noise when it arrived on the exchange just over a month ago. On Sept. 16, SNOW stock went public, and demand for the new issue was robust. This has helped jack its valuation through the roof, as demand far outweighed supply — and still does. Source: rblfmr / Shutterstock.com Let’s put
Summary Square (SQ) is a good company with a recognizable brand. They offer a diversified list of products and services in the financial services industry. The problem is they face very strong competition from new entrants as well as industry heavyweights which will put pressure on future prospects. Even after assuming generous growth and margin
(L-R) Lloyd Blankfein and David Solomon attend NYSCF Annual Summer Cocktail Reception at Private Residence on July 15, 2016 in Sagaponack, NY. Sean Zanni | Patrick McMullan | Getty Images Goldman Sachs is moving to claw back tens of millions of dollars in compensation it’s paid executives including CEO David Solomon and former CEO Lloyd
Is a vaccine the real risk to the market? Stocks are within 1% to 2% of their historic highs because of the belief that: 1) stimulus of some form is coming, 2) the election will not devolve into chaos, and 3) an effective vaccine will be available in early 2021. Five vaccines — from Moderna,
Take a look at some of the biggest movers in the premarket: Coca-Cola (KO) – Coca-Cola beat estimates by 9 cents a share, with quarterly earnings of 55 cents per share. Revenue topped forecasts as well. The partial reopening of theaters and restaurants helped the company’s results, and an organic sales decline of 6% was